Kepler Capital analyst David Evans maintained a Buy rating on Adocia (ADOCY) on June 8 and set a price target of EUR19.00. The company’s shares closed last Tuesday at $11.02.
According to TipRanks.com, Evans is a 4-star analyst with an average return of 8.7% and a 67.3% success rate. Evans covers the Healthcare sector, focusing on stocks such as Quantum Genomics, Innate Pharma, and Crossject SA.
Adocia has an analyst consensus of Moderate Buy, with a price target consensus of $21.06.
See today’s analyst top recommended stocks >>
The company has a one-year high of $13.22 and a one-year low of $9.56. Currently, Adocia has an average volume of 6.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins. The firm has developed Biochaperone proprietary technological platform to enhance the effectiveness of therapeutic proteins. The company’s product pipeline includes biochaprone lispro, biochaparone combo, biochaparone human glucagon etc. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
